Raj Chovatiya, MD, PhD: Advancements in the Management Paradigm for Generalized Pustular Psoriasis

November 10, 2025

Dr. Chovatiya discusses evolving treatment strategies for Generalized Pustular Psoriasis (GPP) and how recent clinical research is reshaping the management paradigm for this severe inflammatory condition. His presentation highlights emerging targeted therapies, particularly inhibitors designed to block the Interleukin-36 pathway, which plays a key role in the pathogenesis of GPP.

Topics Covered

Clinical characteristics and severity of generalized pustular psoriasis
Best practices for managing acute flares and ongoing disease activity
Evidence supporting IL-36 pathway inhibitors in clinical research
How targeted therapies are changing treatment approaches for GPP

Explore Related Resources

Raising Awareness for Generalized Pustular Psoriasis
Assessing Systemic GPP Treatment With Targeted Therapy

MORE EXPERT PERSPECTIVES IN GENERALIZED PUSTULAR PSORIASIS

James Song, MD, FAAD: Assessing Systemic GPP Treatment With Targeted Therapy

James Song, MD, FAAD, discusses the severity of generalized pustular psoriasis for patients and options for treatment.

Scott Worswick, MD: Dosing Strategies for Treating Generalized Pustular Psoriasis

Scott Worswick, MD, discusses dosing options for patients with GPP during the treatment of acute flares and maintenance therapy.

Johann E. Gudjonsson, MD, PhD: Mitigating Low-grade Inflammatory Activity in Generalized Pustular Psoriasis

Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP

Tina Bhutani, MD: Raising Awareness for Generalized Pustular Psoriasis

Dr. Tina Bhutani highlights the National Psoriasis Foundation’s efforts to raise awareness for generalized pustular psoriasis and support affected patients. Topics Covered: GPP awareness initiatives

Tina Bhutani, MD: Reviewing the Pathogenesis of Generalized Pustular Psoriasis

Dr. Bhutani reviews the underlying disease mechanisms of Generalized Pustular Psoriasis (GPP), focusing on the role of inflammatory signaling pathways that drive the condition. Her

Tina Bhutani, MD: Assessing the Quality of Life Impact in Patients with Generalized Pustular Psoriasis

Dr. Bhutani examines the significant quality-of-life burden associated with Generalized Pustular Psoriasis (GPP), a rare and severe inflammatory skin condition. Her discussion highlights how frequent

Tina Bhutani, MD: Diagnosing Patients with Generalized Pustular Psoriasis

Dr. Bhutani discusses the diagnostic challenges associated with Generalized Pustular Psoriasis (GPP), a rare and often unpredictable inflammatory skin disease. Her presentation highlights the importance

JCAD Archives